Pepkor Holdings ZAR 4.9 billion secondary offering
The accelerated bookbuild transaction represented approximately 7.2% of Pepkor’s issued share capital
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
CureVac $250 million follow-on offering
We advised CureVac on the equity offering
RxSight $50 million follow-on offering
The stock is listed on the Nasdaq Global Market
Xponential Fitness $122.5 million secondary offering
We advised Xponential Fitness on the offering
ADC Therapeutics secondary offering
We advised ADC Therapeutics on the registered secondary offering of its shares
Roivant Sciences $230 million stock offering
We advised the company on its SEC-registered offering
TD SYNNEX $502 million secondary offering
The shares are listed on the NYSE
Pacific Biosciences $201.25 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Precigen $75 million follow-on offering
We advised Precigen on the SEC-registered offering
Deciphera Pharmaceuticals $135.1 million common stock offering
The common stock is listed on the Nasdaq Global Select Market